
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb is attractive because its growth is increasingly led by differentiated, higher-margin franchises across all three segments, with MIEBO revenue up 42% year over year to $119M in 3Q26 and prescription dry eye up 22%, while premium IOLs and daily SiHy lenses are also taking share. Operationally, 3Q26 revenue of $1.375B was in line, but adjusted EBITDA of $325M beat expectations on 64.7% gross margin, disciplined SG&A and R&D, and management raised FY26 EBITDA guidance by $65M to $1.090B–$1.140B. The company also has adequate liquidity with $515M of cash and restricted cash against $5.095B of long-term debt, and the combination of margin expansion, product innovation, and disciplined capital allocation supports a constructive fundamental outlook.
Bears say
Bausch & Lomb is facing a weakened fundamental setup because leadership instability, with Brent Saunders’ departure, an interim CEO who also runs Bausch Health, and no announced permanent search, leaves strategy and execution clouded while BHC still controls about 87% of the shares and the float remains limited near 13%. Regulatory risk is also elevated after the FDA’s September Warning Letter on cGMP violations at the Tampa facility, even as remediation runs into later this year or early 2027, and that overhang adds uncertainty to production quality and investor confidence. Operationally, the business is vulnerable to under-scaled Surgical margins, potential softness in MIEBO and contact lens demand, and competitive and macro pressures, all of which could keep revenue and EBITDA growth below expectations.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Bausch + Lomb Corp (BLCO) Forecast
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares